This is the authors' abstract. We don't add key points for this paper.
Sarcopenia is an age-related loss of muscle strength, mass, and skeletal muscle function, and is a common disease with serious adverse consequences. Although the pathophysiology of sarcopenia has not been fully studied, there are common mechanisms between sarcopenia and the phenomenon of accelerated aging observed in diabetes mellitus (DM). Hypoglycemic drugs currently used for the treatment of type 2 diabetes (DM2) may have mechanisms of action that are important for the prevention and treatment of sarcopenia in both patients with and without DM2. This literature review summarizes the data of modern clinical and preclinical studies on the possible effect of hypoglycemic drugs on muscle mass, strength and function, treatment and prevention of sarcopenia in DM2 and without it. It was found that studies of this relationship in patients with DM2 dominated. The limited amount of research in patients without DM2 does not allow us to develop tactics for the prevention and therapy of sarcopenia in full. In this regard, it is necessary to continue research in this direction.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dolgikh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: